Aclarion, Inc., a commercial-stage healthcare technology company, announced that CEO Brent Ness will attend LSI USA 2026, a premier conference for MedTech innovators, investors, and industry leaders. The event, scheduled for March 16-20, 2026 in Dana Point, California, brings together key stakeholders focused on accelerating healthcare technology innovation. During the conference, Ness will meet with investors and potential industry partners to discuss Aclarion's progress with Nociscan, the company's proprietary magnetic resonance spectroscopy platform.
Nociscan represents a significant advancement in addressing chronic low back pain, a condition affecting millions worldwide and representing a substantial healthcare burden. The platform leverages biomarkers and proprietary augmented intelligence algorithms to help physicians distinguish between painful and non-painful discs in the lumbar spine. This technology provides critical insights that, when used alongside other diagnostic tools, can help physicians optimize treatment strategies for patients suffering from persistent back pain.
The importance of this technology lies in its potential to transform how chronic low back pain is diagnosed and treated. Traditional diagnostic methods often struggle to pinpoint the exact source of pain, leading to suboptimal treatment outcomes and prolonged patient suffering. By noninvasively identifying which discs may be causing pain, Nociscan offers physicians more precise information to guide treatment decisions. This could lead to more targeted interventions, potentially reducing unnecessary procedures and improving patient outcomes.
For more News from Aclarion, please visit their newsroom. The company's technology works by receiving magnetic resonance spectroscopy data from MRI machines through a cloud connection. Proprietary signal processing techniques then extract and quantify chemical biomarkers associated with disc pain, which are analyzed using AI algorithms to indicate potential pain sources.
The broader implications of this technology extend beyond individual patient care to the healthcare system as a whole. More accurate diagnoses could lead to reduced healthcare costs by minimizing ineffective treatments and procedures. For the medical technology industry, Aclarion's approach demonstrates how artificial intelligence and biomarker analysis can be combined to address complex medical challenges. The company's participation at LSI USA 2026 highlights the growing intersection of AI and medical diagnostics, a trend that is reshaping how healthcare providers approach chronic conditions.
As Aclarion continues to advance its technology, the potential impact on patients suffering from chronic low back pain could be substantial. The condition represents one of the most common reasons for healthcare visits and disability worldwide, creating significant economic and quality-of-life burdens. Technologies like Nociscan that offer more precise diagnostic capabilities could help address this widespread challenge by providing physicians with better tools to understand and treat the underlying causes of pain.
